Arginine-glycine-aspartate (RGD) peptide binds to the integrin αvβ3, which plays a crucial role in tumor angiogenesis and metastasis. Previously developed 68Ga-labeled cyclic RGD peptides are rapidly excreted from the circulatory system. In the present study, we developed a 68Ga-labeled cyclic RGD peptide with a biphenyl group between the chelator and RGD peptide, i.e., 68Ga-NOTA-biphenyl-c(RGDyK). Then, we performed the comparison with the reference compound, i.e., 68Ga-NOTA-c(RGDyK). 68Ga-NOTA-biphenyl-c(RGDyK) was 37% less hydrophilic than 68Ga-NOTA-c(RGDyK). For positron emission tomography imaging, 68Ga-NOTA-biphenyl-c(RGDyK) had a longer retention time and showed a higher signal-to-noise ratio in tumors than 68Ga-NOTA-c(RGDyK). However, the biphenyl-radiopeptide displayed the relatively high non-specific binding. From these perspectives, incorporation of the biphenyl group to the RGD generates pros and cons.
Bibliographical noteFunding Information:
68Ga-NOTA-RGD peptides showed enhanced tumor uptake as well as increased non-specific binding. From these perspectives, we demonstrated that adapting biphenyl group on the RGD peptide has pros and cons. Acknowledgments. This work was supported by Nuclear Research and Development Program of the National Research Foundation of Korea (NRF) grant funded by of the Korean government (No. 2017M2A2A6A02019904) and a grant of the Korea Institute of Radiological and Medical Sciences (KIRAMS) funded by the Ministry of Science, ICT & Future Planning, Republic of Korea (No. 1711045539; 1711045541/50461-2017).
© 2017 Korean Chemical Society, Seoul & Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
All Science Journal Classification (ASJC) codes